Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Hum Mutat ; 35(1): 117-28, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24130121

ABSTRACT

Xeroderma pigmentosum variant (XP-V) is a rare genetic disease, characterized by some sunlight sensitivity and predisposition to cutaneous malignancies. We described clinical and genetic features of the largest collection ever published of 23 XPV patients (ages between 21 and 86) from 20 unrelated families. Primary fibroblasts from patients showed normal nucleotide excision repair but UV-hypersensitivity in the presence of caffeine, a signature of the XP-V syndrome. 87% of patients developed skin tumors with a median age of 21 for the first occurrence. The median numbers of basal-cell carcinoma was 13 per patient, six for squamous-cell carcinoma, and five for melanoma. XP-V is due to defects in the translesion-synthesis DNA polymerase Polη coded by the POLH gene. DNA sequencing of POLH revealed 29 mutations, where 12 have not been previously identified, leading to truncated polymerases in 69% of patients. Four missense mutations are correlated with the protein stability by structural modeling of the Polη polymerase domain. There is a clear relationship between the types of missense mutations and clinical severity. For truncating mutations, which lead to an absence of or to inactive proteins, the life-cumulated UV exposure is probably the best predictor of cancer incidence, reinforcing the necessity to protect XP-Vs from sun exposure.


Subject(s)
DNA-Directed DNA Polymerase/genetics , DNA-Directed DNA Polymerase/metabolism , Skin Neoplasms/genetics , Xeroderma Pigmentosum/genetics , Xeroderma Pigmentosum/pathology , Adult , Aged , Aged, 80 and over , Caffeine , Carcinoma, Basal Cell/epidemiology , Carcinoma, Basal Cell/genetics , Carcinoma, Basal Cell/pathology , Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/pathology , Cells, Cultured , DNA Repair , Female , Fibroblasts/metabolism , Genetic Variation , Genotype , Humans , Male , Melanoma/epidemiology , Melanoma/genetics , Melanoma/pathology , Middle Aged , Models, Molecular , Mutation, Missense , Phenotype , Protein Stability , Retrospective Studies , Skin Neoplasms/epidemiology , Skin Neoplasms/pathology , Ultraviolet Rays , Xeroderma Pigmentosum/complications , Young Adult
2.
PLoS One ; 8(11): e78678, 2013.
Article in English | MEDLINE | ID: mdl-24236034

ABSTRACT

Xeroderma pigmentosum group C (XP-C) is a rare human syndrome characterized by hypersensitivity to UV light and a dramatic predisposition to skin neoplasms. XP-C cells are deficient in the nucleotide excision repair (NER) pathway, a complex process involved in the recognition and removal of DNA lesions. Several XPC mutations have been described, including a founder mutation in North African patients involving the deletion of a TG dinucleotide (ΔTG) located in the middle of exon 9. This deletion leads to the expression of an inactive truncated XPC protein, normally involved in the first step of NER. New approaches used for gene correction are based on the ability of engineered nucleases such as Meganucleases, Zinc-Finger nucleases or TALE nucleases to accurately generate a double strand break at a specific locus and promote correction by homologous recombination through the insertion of an exogenous DNA repair matrix. Here, we describe the targeted correction of the ΔTG mutation in XP-C cells using engineered meganuclease and TALEN™. The methylated status of the XPC locus, known to inhibit both of these nuclease activities, led us to adapt our experimental design to optimize their in vivo efficacies. We show that demethylating treatment as well as the use of TALEN™ insensitive to CpG methylation enable successful correction of the ΔTG mutation. Such genetic correction leads to re-expression of the full-length XPC protein and to the recovery of NER capacity, attested by UV-C resistance of the corrected cells. Overall, we demonstrate that nuclease-based targeted approaches offer reliable and efficient strategies for gene correction.


Subject(s)
Deoxyribonucleases/genetics , Xeroderma Pigmentosum/therapy , Base Sequence , Cell Line , DNA Cleavage , DNA Methylation , DNA Repair , DNA-Binding Proteins/genetics , Epigenesis, Genetic , Genetic Therapy , Humans , Mutagenesis , Phenotype , Protein Engineering
3.
J Invest Dermatol ; 130(6): 1537-42, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20054342

ABSTRACT

Xeroderma pigmentosum (XP) is a rare autosomal recessive disorder that is associated with an inherited defect of the nucleotide excision repair pathway (NER). In this study, we investigated the involvement of XP genes in 86 XP patients belonging to 66 unrelated families, most of them consanguineous and originating from Maghreb. Sequencing analysis was performed either directly (44 probands) or after having previously characterized the involved XP gene by complementation assay (22 families). XPC and XPA mutations were respectively present in 56/66 and 8/66 probands. Strikingly, we identified the same homozygous frameshift mutation c.1643_1644delTG (p.Val548AlafsX25) in 87% of XP-C patients. Haplotype analysis showed a common founder effect for this mutation in the Mediterranean region, with an estimated age of 50 generations or 1,250 years. Among 7/8 XP-A patients, we found the previously reported nonsense homozygous XPA mutation (p.Arg228X). Six mutations--to our knowledge previously unreported--(five in XPC, one in XPA) were also identified. In conclusion, XPC appears to be the major disease-causing gene concerning xeroderma pigmentosum in North Africa. As the (p.Val548AlafsX25) XPC mutation is responsible for a huge proportion of XP cases, our data imply an obvious simplification of XP molecular diagnosis, at least in North Africa.


Subject(s)
DNA-Binding Proteins/genetics , Founder Effect , Mutation/genetics , Xeroderma Pigmentosum/ethnology , Xeroderma Pigmentosum/genetics , Adolescent , Adult , Africa, Northern/epidemiology , Child , Child, Preschool , Cohort Studies , DNA Repair/genetics , Female , Haplotypes , Heterozygote , Humans , Male , Middle Aged , Phenotype , Xeroderma Pigmentosum/epidemiology , Xeroderma Pigmentosum Group A Protein/genetics , Young Adult
4.
Mutagenesis ; 22(5): 343-51, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17630408

ABSTRACT

Cells from Cockayne syndrome patients are characterized by a deficiency in transcription-coupled repair (TCR) of UV-induced lesions. These cells have also been shown to be sensitive to oxidative stress and defective in TCR of some oxidative lesions. Because some discrepancies about this pathway have been recently reported in the literature, we describe here a system that allows us to analyze the effect of a unique 8-oxoguanine (8-oxoG) lesion on gene transcription in vivo. We have constructed nonreplicative shuttle vectors containing a single 8-oxoG in the transcribed strand of the luciferase reporter gene. We have positioned this unique lesion in different sequence contexts and we have tested the effect of two promoters with different transcriptional strength on the level of transcriptional bypass/pause due to the presence of the lesion. When we transfected DNA repair-deficient mouse cell lines with these shuttle vectors, we found a approximately 50% decrease in relative luciferase activity in Ogg1(-/-) and Csb(-/-) embryonic mouse cell lines. In Csb(-/-)/Ogg1(-/-) cells, this decrease was even more important achieving eventually up to 90% inhibition of luciferase expression depending upon the promoter strength and the position of the lesion. These results show clearly that a unique 8-oxoG exhibits different effect on gene expression depending upon the nucleotidic sequence around it and needs the wild-type activities of Csb and Ogg1 proteins to be fully repaired.


Subject(s)
DNA Repair , Guanine/analogs & derivatives , Mutagenicity Tests , Transcription, Genetic/genetics , Animals , Bacteria/drug effects , Bacteria/genetics , Base Sequence , Cell Line , Cockayne Syndrome/genetics , DNA Glycosylases/genetics , DNA Glycosylases/physiology , DNA Repair Enzymes/genetics , DNA Repair Enzymes/physiology , Embryo, Mammalian/cytology , Fibroblasts/metabolism , Guanine/metabolism , Guanine/pharmacology , Luciferases/analysis , Luciferases/genetics , Mice , Mice, Knockout , Mutagenesis , Poly-ADP-Ribose Binding Proteins , Promoter Regions, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL
...